Latest News - Pfizer
Top Corporates Hub
Pfizer
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer
02.09.2025 12:00
Study to explore the palazestrant-atirmociclib combination in approximately 35 patients with initiation anticipated in H2 2025 Results to inform potential pivotal Phase 3 trial of novel combination in frontline metastatic breast cancer setting SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for bre
Pfizer: Pipeline Monetization Shows Great Promise - Rich Yields Pending Re-Rating
02.09.2025 10:10
PFE has shown great efforts in operational efficiencies, as observed in the richer profit margins, the expanding cash flows, and the healthier balance sheet.
Pfizer Inc. (PFE)’s Updated COVID-19 Vaccine COMIRNATY LP.8.1 Gets FDA Approval, Ships Nationwide
02.09.2025 08:28
We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Pfizer Inc. stands fifth among them. Pfizer Inc. (NYSE:PFE), a global pharmaceutical leader, continues to drive growth through innovation, commercial execution, and operational efficiency. The company’s portfolio spans vaccines and treatments for a range of diseases, including its […]
3 High-Yield Dividend Stocks You Can Buy in September and Hold Forever
02.09.2025 08:21
With an average yield above 6%, these stocks could do a lot to raise your passive income stream.
My 3 Favorite Stocks to Buy Right Now
27.08.2025 13:45
Contrary to a common assumption at this time, not every stock is priced too richly or poses too much risk. Several underappreciated and undervalued names are just waiting to be found.
Renovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced Diagnostics
27.08.2025 13:45
LOS ANGELES, CALIFORNIA / ACCESS Newswire / August 27, 2025 / Renovaro Inc. (NASDAQ:RENB) today announced that it will change its corporate name to Lunai Bioworks, Inc. to better reflect its strategic direction and growing expertise in AI-powered ...
HER2+ Breast Cancer Clinical Trials Analysis Report 2025 - Enhance Your Understanding of Trial Counts and Enrollment Trends Across G7 & E7 Countries
27.08.2025 10:06
Featuring Roche, Pfizer, GSK, Novartis, and AstraZeneca Among Other Industry PlayersDublin, Aug. 27, 2025 (GLOBE NEWSWIRE) -- The "Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) - Global Clinical Trials Review, 2025" has been added to ResearchAndMarkets.com's offering. The report provides an in-depth analysis of the clinical trial landscape for HER2+ Breast Cancer. It offers crucial data on trial numbers, enrollment, and regional distribution, allowing stak
Trump Administration Plans To Pull COVID-19 Vaccines Off Market 'Within Months'
27.08.2025 00:31
The Trump administration is preparing to remove COVID-19 vaccines from the U.S. market "within months," according to a close associate of Health and Human Services Secretary Robert F. Kennedy Jr. Shortly after the update, COVID-19 vaccine stocks, ...
GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU
26.08.2025 13:40
Gilead secures EU approval for twice-yearly HIV prevention shot Yeytuo, backed by strong trial data and expanded market protection.
Is There Now an Opportunity in Pfizer After FDA Covid Vaccine Review for Children?
26.08.2025 10:12
Thinking about what to do with your Pfizer shares? You are definitely not alone, especially as sentiment around the stock feels conflicted. Over the past week, Pfizer slid a modest 0.7%, and for the year so far, it is down 5.5%. But here is where it gets interesting: the stock did manage to gain 1.4% over the past 30 days. Even with a 3-year decline of 35.4%, recent price action hints that investors are weighing new risks and opportunities. In other words, Pfizer is not just treading water;...
Pfizer: Stagnation Is An Investment Opportunity
21.08.2025 03:47
Pfizer offers an attractive near-7% dividend yield, appealing for income-focused investors. Find out why PFE stock is a Buy.
Pfizer: sued in Europe by Enanta for patent infringement
21.08.2025 03:14
US biotech company Enanta Pharmaceuticals announced on Wednesday that it had filed a complaint with the EU's Unified Patent Court against pharmaceutical giant Pfizer, accusing it of infringing a...
MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer
19.08.2025 15:37
Merck's ifinatamab deruxtecan wins FDA Breakthrough Therapy status for treating adults with extensive-stage small cell lung cancer.
Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue?
19.08.2025 13:08
Pfizer's oncology portfolio, boosted by Seagen and strong drug sales, fuels Q2 growth and positions the company for future cancer treatment gains.
Pfizer Canada and HPIC Mark 30 Years of Humanitarian Partnership Delivering Global Health Impact
19.08.2025 12:00
On World Humanitarian Day, Pfizer Canada is proud to mark 30 years of partnership with Health Partners International of Canada (HPIC), a collaboration that has delivered over $70 million worth of life-saving medicines to vulnerable communities across 58 countries.
Is Pfizer's 6.8%-Yielding Dividend Too Good to Be True?
19.08.2025 08:50
Pfizer's yield is high, and so too is its payout ratio.
Pfizer: This Is What Bulls Waited For
16.08.2025 04:19
Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS guidance. See more on PFE stock here.
If You Invested $10K In Pfizer Stock 10 Years Ago, How Much Would You Have Now?
14.08.2025 12:01
Pfizer Inc. (NYSE:PFE) discovers, develops, manufactures, and sells biopharmaceutical products in the U.S. and internationally. It is set to report its Q3 2025 earnings on Oct. 28. Wall Street analysts expect the company to post EPS of $0.86, down ...
3 Reasons Pfizer's 7%-Yielding Dividend Is Getting Safer
13.08.2025 08:51
This big pharma company's juicy dividend is looking even more attractive.
PFE Q2 Deep Dive: Margin Expansion and R&D Pipeline Fuel Outlook Amid Policy Uncertainty
13.08.2025 04:24
Global pharmaceutical company Pfizer (NYSE:PFE) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.3% year on year to $14.65 billion. The company expects the full year’s revenue to be around $62.5 billion, close to analysts’ estimates. Its non-GAAP profit of $0.78 per share was 35.9% above analysts’ consensus estimates.